Your session is about to expire
← Back to Search
Vorolanib + Nivolumab for Thoracic Tumors
This trial is testing a new combination treatment for lung cancer patients who have not responded to other treatments.
- Refractory Thoracic Tumors
- Thymic Carcinoma
- Small Cell Lung Cancer
- Non-Small Cell Lung Cancer
Inclusion CriteriaYou will be eligible if you check “Yes” for the criteria below
Study ObjectivesOutcome measures can provide a clearer picture of what you can expect from a treatment.
Side effects dataFrom 2022 Phase 3 trial • 541 Patients • NCT02041533
Awards & Highlights
Find a Location
Who is running the clinical trial?
- You have a known or suspected autoimmune disease that is currently active.You have had a solid tumor transplant.You have either tried and failed at least one type of treatment, or you have chosen not to receive chemotherapy.You are 18 years old or older, regardless of gender.You have a specific type of lung cancer (NSCLC) with certain genetic mutations, and you have already tried medication taken by mouth for it. You may have also tried other treatments before.You have a detectable and measurable tumor that can be monitored by CT or MRI scans using a specific set of criteria called RECIST 1.1.You have enough infection-fighting white blood cells, specifically a count of at least 1,500 per microliter.You have wounds that are not healing, significant bleeding that is ongoing, or difficulty swallowing pills.You have a serious heart condition.You have another type of cancer that is currently active or was diagnosed within the past 2 years that could affect your participation in the study.You have read and agreed to a document that explains the study and you have signed and dated it to show that you understand and consent to participate.If you have Small Cell Lung Cancer, you must have tried platinum-based chemotherapy and up to three other treatments for stage IV cancer. However, you cannot have taken an oral VEGF TKI before. You can have taken an anti-PD-1 or PD-L1 medication before.You have had a major surgery or significant injury within 28 days before starting the study treatment that includes bevacizumab, or any other anti-cancer treatment.You are able to perform daily activities without significant limitations or with only slight limitations.You have advanced lung cancer and have already received chemotherapy, but it didn't work or you declined it. You have not yet received any immunotherapy or certain targeted drugs. You may have received up to three different treatments for your cancer.You have advanced non-small cell lung cancer and have already tried a certain type of immunotherapy called checkpoint inhibitor. You have also tried up to three other treatments for this stage of cancer, but none of them included a specific type of medication.You have thymic carcinoma, but you cannot have surgery at the time of the study. You may have received other treatments before, but not ones that include certain drugs.You haven't fully recovered from the side effects of your previous cancer treatment.You have had an allergic reaction or couldn't tolerate specific cancer treatments before.
Frequently Asked Questions
Are there any other scientific trials that have been conducted related to Nivolumab?
"Nivolumab, which was initially introduced to research in 2012 by Local Institution, has already seen 252 clinical trials concluded. Of the 718 active studies taking place now, a substantial amount are concentrated around Philadelphia, Pennsylvania."
How many participants are involved in this medical experiment?
"This clinical trial is not presently recruiting participants. The information was initially posted on July 10th 2018 and the record was last revised on September 21st 2022. If you are investigating other studies, there are 1,701 medical trials actively accepting patients with small cell lung carcinoma and 718 for Nivolumab which require volunteers."
Is this an innovative exploration of the subject?
"In the 8 years since its initial trial in 2012, Nivolumab has been studied extensively. Presently there are 718 active clinical trials for this drug across 2356 cities in 49 countries. Initially sponsored by Ono Pharmaceutical Co Ltd., it involved 659 participants and successfully passed Phase 1 & 2 of approval stages. In total, 252 studies have been conducted concerning this medication up to now."
What are the typical ailments that Nivolumab is employed to address?
"Nivolumab is suitable for treating cancerous tumours, as well as unresectable melanoma, esophageal adenocarcinoma with metastasis, and squamous cell carcinomas."
Is there an opportunity for individuals to currently join this investigation?
"This clinical trial is not presently enrolling candidates. It was first posted on July 10th 2018 and had its last edit done on September 21st 2022. If you seek other studies, there are 1,701 trials actively recruiting participants with small cell lung carcinoma, as well as 718 offering Nivolumab treatments."
Are there numerous healthcare facilities administering this research across North America?
"The 8 medical centres hosting this clinical trial include Fox Chase Cancer Center in Philadelphia, Stanford Cancer Institute in Palo Alto, and Providence Cancer Institute Franz Clinic located in Portland. Additionally, there are 5 more places across the United States that are accepting participants for this study."
Share this study with friends